{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T10:05:31Z","timestamp":1771236331092,"version":"3.50.1"},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T00:00:00Z","timestamp":1579132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Previous attempts to develop a pragmatic human model for testing new anti\u2010migraine drugs, have failed. Calcitonin gene\u2010related peptide (CGRP) induces a mild headache in healthy volunteers and migraine\u2010like headache in migraine patients. The induced headache must respond to already established migraine treatment for validation. Thus, the objective of the study was to test the effect of sumatriptan against CGRP\u2010induced symptoms in an attempt to validate CGRP\u2010induced headache as a model for drug testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Thirty healthy volunteers were recruited to receive a 2\u2010hour infusion of CGRP on 2 separate days. The participants were pretreated with sumatriptan 1 day and with placebo the other day in a randomized double\u2010blind cross\u2010over fashion. During the infusion, a questionnaire about headache and side effects was administered. Electrocardiography, heart rate, blood pressure, dermal blood flow, and diameter of peripheral arteries were monitored during the infusion. Participants were carefully instructed to fill out a headache questionnaire at home until 12\u00a0hours after the infusion start. Primary endpoints are difference between the sumatriptan day and the placebo day in area under the headache score curve (AUC) 0\u20102\u00a0hours after infusion start and in headache intensity 2\u00a0hours after infusion start. The study was conducted at the Danish Headache Center in Glostrup, Denmark.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CGRP\u2010induced headache in 86% (25\/29) of the participants on the sumatriptan day and in 96% (28\/29) of the participants on the placebo day. There was no difference in AUC\n                      <jats:sub>headache, 0\u20102\u00a0hours<\/jats:sub>\n                      between the days (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a0.794). There was a statistically significant decrease in mean atrial pressure (MAP) over time on both days with a16.2% reduction on the sumatriptan day and a 14.8% reduction on the placebo day (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.001) and a statistically significant increase in heart rate (HR) over time on both days (from mean 57.5 at baseline to mean 105.4 at 120\u00a0minutes on the sumatriptan day and from mean 60.2 at baseline to 105.8 at 120\u00a0minutes on the placebo day,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.001). The diameter of peripheral arteries increased statistically significant on both days (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Sumatriptan does not influence headache score, accompanying symptoms or other symptoms induced by CGRP. Furthermore, a 2\u2010hour CGRP infusion causes a wide range of side effects and does not induce more headache than the usual 20\u2010minute infusion. Thus, the prolonged infusion of CGRP in healthy volunteers is not a valid and pragmatic model for testing new anti\u2010migraine drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.13747","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T03:53:05Z","timestamp":1579146785000},"page":"665-676","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Sumatriptan Does Not Antagonize CGRP\u2010Induced Symptoms in Healthy Volunteers"],"prefix":"10.1111","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8265-3851","authenticated-orcid":false,"given":"Katrine","family":"Falkenberg","sequence":"first","affiliation":[{"name":"Danish Headache Centre Department of Neurology Rigshospitalet Glostrup University of Copenhagen Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helene","family":"R\u00f8nde Bjerg","sequence":"additional","affiliation":[{"name":"Danish Headache Centre Department of Neurology Rigshospitalet Glostrup University of Copenhagen Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nooshin","family":"Yamani","sequence":"additional","affiliation":[{"name":"Danish Headache Centre Department of Neurology Rigshospitalet Glostrup University of Copenhagen Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes","family":"Olesen","sequence":"additional","affiliation":[{"name":"Danish Headache Centre Department of Neurology Rigshospitalet Glostrup University of Copenhagen Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,1,16]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102415583986"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102416636095"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0841-7"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0890-y"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2002.00310.x"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410368444"},{"key":"e_1_2_13_8_1","unstructured":"Fors\u00f8gsperson.dk. Raske deltagere s\u00f8ges! Udvikling af model til at teste nye migr\u00e6ne\u2010midler.Nationalt center for clinical trialregistrations."},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413485658"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2013.03.010"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2010.05.016"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2202-12-112"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2003.09.021"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2013"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00315279"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/123.9.1830"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2011.01861.x"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418798611"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2002.00310.x"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22292"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(02)00173-0"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(91)90165-8"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2000.00131.x"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.19-09-03423.1999"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2012.01.005"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410330109"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2005.00836.x"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.13747","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.13747","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.13747","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:27:20Z","timestamp":1762075640000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.13747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,16]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1111\/head.13747"],"URL":"https:\/\/doi.org\/10.1111\/head.13747","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,16]]},"assertion":[{"value":"2019-12-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}